Epigenetic Clocks ("Biological Age" Tests)
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
DNA methylation patterns at specific genomic sites, combined by algorithm into an estimate of “biological age.” The best-known versions — the Horvath clock, GrimAge, PhenoAge and DunedinPACE — underpin most consumer biological-age tests. Methylation does change with age in a fairly predictable pattern, and some clocks, GrimAge and DunedinPACE in particular, correlate with future mortality and morbidity better than chronological age alone. That is a genuine and interesting finding about populations, which is not the same as a finding about you.
A 2026 review, “From population science to the clinic? Limits of epigenetic clocks as personal biomarkers,” concluded that epigenetic clocks fail to meet common standards for clinical utility compared with established biomarkers, and that applying them to individual-level decision-making can be uninformative and potentially harmful. It cites unresolved technical issues — clock construction methods, sample handling, computational implementation — alongside biological ones: tissue specificity, sensitivity to environmental and sociodemographic context, and limited replication across diverse populations. Its conclusion is that even if those hurdles are eventually cleared, epigenetic clocks as currently understood should not be used to make individual-level decisions.
"From population science to the clinic? Limits of epigenetic clocks as personal biomarkers." PubMed: PMID 41403206
Singapore guidance
Not covered in the current review
Singapore’s national screening committee has not reviewed this test in the current volume of its report, which covers nine conditions. That is not a verdict either way.
Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.
What you would actually pay
- Healthier SG
- Not subsidised
- MediSave
- Not among the screenings named for outpatient claims
Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.
What it costs when it is wrong
- Basis
- No published harm criterion found
- Severity
- Not documented
Not covered in the current volume of the committee’s report, so no harm criterion was found either way.
An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.
Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.
FAQ
Is the Epigenetic Clocks ("Biological Age" Tests) worth doing in Singapore?
For adults without symptoms, Epigenetic Clocks ("Biological Age" Tests) sits at the emerging grade on our evidence scale. It typically costs S$400–700 in Singapore. There is no routine interval: research tool, not a validated individual-tracking test. It is most appropriate for not currently recommended as a basis for any individual health decision.
Weighing this against something else? Compare it with two other tests → · Price it inside a panel →